Journals / Fırat Tıp Dergisi / 2019 / Cilt: 24 - Sayı: 3

The Effect of VEGF and CD44 Expressions on Axillary Lymph Node Metastasis in Breast Carcinom

Meme Karsinomunda VEGF ve CD44 Ekspresyonunun Aksiller Lenf Nodu Metastazına Etkisi

Pages
137–144
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, lymph node metastasis and CD44 and VEGF expression were found to be statistically related (Anova p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, it was aimed to investigate the relationship of CD44 and VEGF expression to axillary lymph node metastasis that is one of the most important prognostic factors in invasive breast carcinoma.
📊
Key Findings & Data:Material and Method: This retrospective study included 62 invasive breast carcinoma patients who underwent modified radical mastectomy and axillary lymph node dissection between 1990-2000 in Atatürk University Faculty of Medicine (FUTF) Department of Pathology.
💡
Conclusion & Impact:However, lymph node metastasis and CD44 and VEGF expression were found to be statistically related (Anova p
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, it was aimed to investigate the relationship of CD44 and VEGF expression to axillary lymph node metastasis that is one of the most important prognostic factors in invasive breast carcinoma. Material and Method: This retrospective study included 62 invasive breast carcinoma patients who underwent modified radical mastectomy and axillary lymph node dissection between 1990-2000 in Atatürk University Faculty of Medicine (FUTF) Department of Pathology. The pathological specimens of this patients were evaluated in terms of classical prognostic factors of breast cancer. Afterwards, immunohistochemical staining was performed using the streptavidin-biotin peroxidase method to determine CD44 and VEGF expression in tumor cells. Results: The mean age at the time of diagnosis was 50.22±11.57 years for patients. Seventeen of the cases (32.2%) had no lymph node metastasis. Twenty-one (33.9%) of 42 patients with lymph node involvement had 1 to 3 metastases and 24 (38.7%) had 4 to 9 metastases. There was no signifi- cant correlation between CD44 and VEGF expression and some classical prognostic factors such as age, macroscopic tumor diameter, lymphovascu- lar invasion, and inflammatory reaction. However, lymph node metastasis and CD44 and VEGF expression were found to be statistically related (Anova p

Özet

Amaç: Bu çalışmada, CD44 ve VEGF ekspresyonunun meme karsinomunda önemli prognostik faktörlerinden biri olan aksiller lenf nodu metastazı ile ilişkisinin araştırılması amaçlanmıştır. Gereç ve Yöntem: Bu retrospektif çalışmaya, Atatürk Üniversitesi Tıp Fakültesi (FÜTF) Patoloji Anabilim Dalı'nda 1990-2000 yılları arasında modifiye radikal mastektomi ve aksiller lenf nodu diseksiyonu yapılan 62 invaziv meme karsinomu hastası dahil edildi. Bu hastalara ait patolojik örnekler meme karsinomunun prognostik faktörleri açısından değerlendirildi. Daha sonra tümör hücrelerinde CD44 ve VEGF ekspresyonunu belirle- mek için streptavidin-biotin peroksidaz yöntemi uygulanarak immunohistokimyasal boyama yapıldı. Bulgular: Hastaların ortalama yaşı 50.7±10.66 olarak belirlendi. Olguların 17’sinde (%27.4) lenf nodu metastazı saptanmadı. Lenf nodu tutulumu olan 45 hastanın 21’inde (%33.9) 1-3 metastaz, 24’ünde ise (%38.7) 4-9 metastaz vardı. Yaş, makroskopik tümör çapı, lenfovasküler invazyon ve inflamatuvar reaksiyon gibi bazı klasik prognostik faktörler ile CD44 ve VEGF ekspresyonu arasında anlamlı korelasyon yoktu. Bununla birlikte, lenf nodu metastazı ile CD44 ve VEGF ekspresyonu istatistiksel olarak ilişkili bulunmuştur (sırasıyla, Anova p

🔖

Cite This Article

ÇALIK, M., ÇALIK, İ., GÜNDOĞDU, B., ŞİPAL, S. (2022). The Effect of VEGF and CD44 Expressions on Axillary Lymph Node Metastasis in Breast Carcinom. Fırat Tıp Dergisi, Cilt: 24 - Sayı: 3, 137–144. https://ajindex.com/articles/513451

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Berner HS, Suo Z, Risberg B et al. Clinicopatho- logical assosiations of CD44 mRNA and protein expression in primary breast carcinomas. Histo- pathology 2003; 42: 546-54
  2. Seemayer CA, Breuer E, Kroll G et al. Incidance and tumour stages of the braest cancer in the re- gion of Aachen, Germany. Eur J Cancer Care 2002; 11: 16-24
  3. Rosai J. Breast. in: Rosai and Ackerman’s Surgical Pathology. Ninth Edition, London: Elsevier İnc 2004: 1763-76
  4. İrgil E: Meme kanseri epidemiyolojisi. İçinde: Ünal G, Ünal H (Editörler). Meme Hastalıkları. İs- tanbul: Nobel Tıp Kitabevleri Ltd 2001: 227-33
  5. Üskent N. Meme kanserinin doğal seyri, gelişimi, risk faktörleri dünyadaki dağlımı ve epidemiyolo- jisi. İçinde: Olgular Işığında Meme Kanseri. İzmir. Turgut Yayıncılık ve Tic. A.Ş 2003: 1-15
  6. Jemal A, Murray T, Ward E et al. Cancer Statistics 2005. CA Cancer J Clin 2005; 55: 259
  7. Özmen V, Fidaner C, Aksaz E et al. Türkiye’de meme kanseri erken tanı ve tarama programlarının hazırlanması “Sağlık Bakanlığı meme kanseri er- ken tanı ve tarama alt kurulu raporu”. Meme Sağ- lığı Dergisi 2009; 5: 125-34
  8. Fentiman IS. Fixed and modifiable risk factors for breast cancer. Int J Clin Pract 2001: 55; 527-30
  9. Weidner N. Breast. In: Weidner N, Cote RJ, Suster S, Weiss LM (Editors). Modern Surgical Patho- logy. First Edition, Philadelphia: Elsevier 2003: 539-628
  10. Sinn HP, Heider KH, Skroch-Angel P et al. Hu- man mammary carcinomas Express homo logues of rat metastasis-associated variants of CD44. Bre- ast Cancer Res Treat 1995: 36; 307-13
  11. Bankfalvi A, Terpe HJ, Breulelmann D et al. Gains and losses of CD44 expression during breast carci- nogenesis and tumour progression. Histopathology 1998: 33;107-16
  12. Tse GMK, Tan PH, Ma TKF et al. CD44 is useful in the differantiation of benign and malignant pa- pillary lesions of the breast. J Clin Pathol 2005: 58; 1185-8
  13. Price EA, Coombe DR, Murray JC. Endothelial CD44 mediates adhesion of a melanoma cell line a quiescent human endothelial cells in vitro. Int J Cancer 1996: 65; 513-8
  14. Ruiz P, Schwarzler C, Gunthert U. CD44 isoforms during differantiation and development. BioEssays 1994: 17; 17-24
  15. Haynes BF, Liao HX, Patton KL. The transmemb- rane hyalunirate receptor (CD44): multiple functi- ons, multipl forms. Cancer Cells 1991: 3; 347-50
  16. Gunthert U: CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993: 184; 47-63
  17. Jansen RHL, Joosten ASR, Arends JW et al. CD44